Avelumab Plus Axitinib Shows Promise in Advanced GIST
METHODOLOGY:
Researchers conducted a phase 2 trial to evaluate the safety and efficacy of avelumab in combination with axitinib among 56 patients with unresectable/metastatic GIST (median age, 60 years) after the failure of standard therapy.
Participants received avelumab 10 mg/kg intravenously every 2 weeks combined with axitinib 5 mg orally twice daily.
The primary endpoint was the 3-month PFS rate; key secondary endpoints included overall survival, disease control rate, duration of response, and adverse events (AEs).
The median follow-up duration was 27.4 months.
TAKEAWAY:
The PFS rate at 3 months was 57.1%, the median PFS was 4.6 months, and the median overall survival was 14.2 months.
A partial response was achieved in 8.9% of patients, and the median duration of response was 18.5 months.
Stable disease was observed in 60.7% of patients, corresponding to a disease control rate of 69.6%.
AEs occurred in 94.6% of patients, with 30.4% experiencing grade 3 or higher events. The most common treatment-related AEs were diarrhoea (33.9%), thyroid dysfunction (30.4%), hypertension (25%), palmar-plantar erythrodysesthesia (23.2%), myalgia (17.9%), and dysphonia (17.9%).
IN PRACTICE:
"The AXAGIST trial is the largest prospective study evaluating the efficacy of the combination of immune checkpoint inhibitor and a multikinase inhibitor in patients with advanced/metastatic GIST. These results provide unique data on the activity of axitinib in GIST patients, which in combination with avelumab, resulted in long-term clinical benefit in a significant subset of patients," the authors wrote.
SOURCE:
This study was led by Piotr Lukasz Rutkowski, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. It was published online on June 06, 2025, in the European Journal of Cancer .
LIMITATIONS:
This study lacked a comparator arm, which made it impossible to conclude whether the addition of avelumab improves the antitumour activity of axitinib.
DISCLOSURES:
This research and drug supply were financially supported by Pfizer, as part of an alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc. Several authors declared receiving honoraria or having other ties with various sources.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
40 minutes ago
- Medscape
Digital Therapeutic May Reduce Recurrent Suicide Attempts
TOPLINE: A smartphone-based digital therapeutic application designed to deliver suicide-focused cognitive-behavioral therapy (CBT) was associated with a sustained reduction in suicidal ideation through 24 weeks post-discharge and a 58% reduced rate of suicide attempts compared to a control application among adult inpatients with prior attempts, a new study showed. However, the study did not meet its primary endpoint of difference between treatments for 'time to first actual suicide attempt' in those with no prior attempts. METHODOLOGY: The multisite, double-blind, randomized clinical trial included more than 300 adults with an increased risk for suicide (mean age, 28 years; 66% women; 67% White) across six psychiatric inpatient units in the US from 2022 to 2024. Of these, 170 had prior suicide attempts. All participants were given treatment as usual during and after enrollment and were randomly assigned to also receive either 12 sessions of CBT educational modules via a smartphone application called OTX-202 (digital therapy group; n = 168) or common information and materials via a control smartphone application (control group; n = 171). The primary outcome was number of days from randomization until first actual suicide attempt. Secondary outcomes were score changes on the Scale for Suicide Ideation and clinician-rated clinical improvement at week 24. Follow-up data were available for 79% of participants, with assessments conducted via remote interview at weeks 4, 8, 12, 24, 52, 78, and 104. TAKEAWAY: Participants in the digital therapy group completed fewer mean number of sessions than those in the control group (4.4 vs 5.9; P = .02), and about 16% and 8% of the groups had at least one suicide attempt during the follow-up (P = .06), respectively. One death by suicide occurred during the study in the control group. Time to first actual suicide attempt and the adjusted rate of suicide attempts did not differ significantly between the treatment groups for those with no prior attempts. The cumulative probability of suicide attempt at 12 months was higher in the digital therapy group than in the control group (18% vs 9%). However, among patients with prior suicide attempts, those in the digital therapy group had a significant reduction in the rate of repeat suicide attempts during the follow-up compared with those in the control group (0.70 vs 1.68 attempts per person-year; adjusted rate ratio, 0.42; P = .04); each completed digital therapy module was associated with a 14% decrease in the suicide attempt rate; and their odds of clinical improvement were higher (odds ratio, 7.6; P = .04). The digital therapy group also showed a sustained reduction in suicidal ideation between weeks 12 and 24, whereas the control group showed an increased suicidal ideation during this period. The number, nature, and severity of adverse events did not differ significantly between the groups at 24 weeks. IN PRACTICE: 'Although suicide-specific therapy is highly effective for reducing suicidal thoughts and urges, finding therapists who know how to do this life-saving therapy after leaving the hospital can be challenging,' lead study investigator Craig J. Bryan, PsyD, the Ohio State University College of Medicine, Columbus, Ohio, said in a press release. Co-investigator Patricia Simon, PhD, Yale School of Medicine, New Haven, Connecticut, added, 'The weeks and months following a suicide crisis and discharge from a hospital are among the highest risk periods for suicide attempts and mortality, making it imperative to offer effective, suicide-specific interventions during this vulnerable window. OTX-202 addresses this critical need.' SOURCE: This study was published online on August 8 in JAMA Network Open. LIMITATIONS: This study was limited by a smaller sample size and baseline differences between treatment groups despite randomization. The results were not generalizable to patients not engaged in hospital settings. The requirement of smartphone ownership potentially excluded patients with low socioeconomic status. The trial also lacked sufficient power to detect differences in suicide deaths. DISCLOSURES: This study was funded by Oui Therapeutics Inc. and the National Institute of Mental Health. Several investigators, including Bryan and Simon, reported having financial and other ties with various sources and receiving funds from Oui Therapeutics Inc. Full details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
a day ago
- Yahoo
Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 12 Best Australian Stocks to Buy Right Now. On August 8, the company announced positive new patient-reported outcomes from participants in its RePOSA Phase 2 trial of IHL-42X to treat obstructive sleep apnoea (OSA). A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The new insights were collected through exit interviews, in line with FDA's guidance on Patient-Focused Drug Development (PFDD). The results build on already compelling data to reinforce the potential of IHL-42X to improve sleep quality, cognitive function, and daily life. Incannex Healthcare Inc. (NASDAQ:IXHL) said that 57.6% of the respondents reported an improvement in their OSA, of which 89.5% described it as a meaningful change to their lives. Some of the reported benefits include better sleep quality, reduced sleepiness during the daytime, feeling fresh in the morning, and other cognitive and daily-life improvements. Joel Latham, President and CEO of Incannex Healthcare Inc. (NASDAQ:IXHL) stated the following on the findings: 'Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug's potential. We believe the findings from the patient exit interviews underscore that these improvements are not just clinical—they are translating into meaningful, positive changes in patients' daily lives. This reinforces our belief that IHL-42X has the potential to significantly shift the treatment paradigm for OSA.' Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage pharmaceutical company developing medicines to treat chronic conditions, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. While we acknowledge the potential of IXHL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
2 days ago
- Fox News
Cancer vaccine shows promise in preventing recurrence of pancreatic, colorectal tumors
An experimental cancer vaccine has shown promise in keeping certain cancers from coming back. In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine (ELI-002 2P) with 25 patients who had been treated for pancreatic and colorectal cancer. The patients had all undergone surgery to remove tumors and showed "signs of minimal residual disease" or traces of DNA, putting them at a high risk of recurrence, according to a UCLA press release. More than 80% of pancreatic cancer patients experience recurrence of the disease after surgery, research shows — and for 40% to 50%, this happens within the first year. For colorectal cancer, the recurrence rate is between 30% and 50% and is most likely to occur within the first two years after surgery. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers. Among the patients who showed the strongest immune response, a majority were still cancer-free nearly 20 months after receiving the vaccine. The findings were published in Nature Medicine. "This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited," said first author of the study, Zev Wainberg, M.D., professor of medicine at the David Geffen School of Medicine at UCLA and researcher in the UCLA Health Jonsson Comprehensive Cancer Center, in the release. "We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected." "The new cancer vaccine from UCLA is very promising as a major tool against these cancers." In another finding, 67% of the patients in the trial showed immune responses to "additional tumor-associated mutations," indicating that the vaccine could be used to suppress "broader anti-tumor activity." One of the benefits of ELI-002 2P, according to the researchers, is that it's considered "off-the-shelf," which means it's a mass-produced, standardized vaccine that doesn't have to be personalized for each individual patient. "This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations," Wainberg said. "It offers a promising approach to generating precise and durable immune responses without the complexity or cost of fully personalized vaccines." The team has already finished enrolling participants for a phase 2 study that will test ELI-002 7P, the next iteration of the vaccine that will target a "broader set" of KRAS mutations, the release stated. The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. It was conducted in conjunction with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center. Dr. Marc Siegel, Fox News senior medical analyst, was not involved in the study but commented that targeted therapies are becoming increasingly important tools in the fight against cancer. "Solid tumors, especially pancreatic, can be difficult to treat because they are not as mutagenic (capable of inducing or causing mutations) as hematological malignancies (blood cancers) or melanoma, for example, so they don't have as many ready targets for immunotherapy," he told Fox News Digital. For more Health articles, visit "The new cancer vaccine from UCLA is very promising as a major tool against these cancers, as it 'programs' the immune system to target these mutations and has been shown in the NATURE study to elicit a strong clinical response."
